Advertisement

Pancreas Cancer

  • Kyle Wang
  • Andrew Z. Wang
  • Joel E. Tepper
Chapter

Abstract

The use of RT for pancreatic cancer is controversial. Though RT increases local control, this has not usually translated to an OS benefit, likely due to the high competing risk of distant metastases. Selection of appropriate candidates for RT is therefore challenging. The use of hypofractionated techniques such as SBRT has been investigated to potentially increase local control, to increase resectability, and to decrease the overall treatment time, minimizing patient burden and delay of systemic therapy. In this chapter, we will review the use of SBRT for pancreatic malignancies.

Keywords

Pancreas cancer SBRT Borderline resectable Locally advanced Duodenum 

References

  1. 1.
    Balaban EP, Mangu PB, Khorana AA, et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(22):2654–68.CrossRefPubMedGoogle Scholar
  2. 2.
    Chuong MD, Springett GM, Freilich JM, et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys. 2013;86(3):516–22.CrossRefPubMedGoogle Scholar
  3. 3.
    Herman JM, Chang DT, Goodman KA, et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2015;121(7):1128–37.CrossRefPubMedGoogle Scholar
  4. 4.
    Mellon EA, Hoffe SE, Springett GM, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 2015;54(7):979–85.CrossRefPubMedGoogle Scholar
  5. 5.
    Pollom EL, Alagappan M, von Eyben R, et al. Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. Int J Radiat Oncol Biol Phys. 2014;90(4):918–25.CrossRefPubMedGoogle Scholar
  6. 6.
    Comito T, Cozzi L, Clerici E, et al. Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study. Technol Cancer Res Treat. 2017;16(3):295–301.CrossRefPubMedGoogle Scholar
  7. 7.
    Mahadevan A, Miksad R, Goldstein M, et al. Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. Int J Radiat Oncol Biol Phys. 2011;81(4):e615–22.CrossRefPubMedGoogle Scholar
  8. 8.
    Shaib WL, Hawk N, Cassidy RJ, et al. A phase 1 study of stereotactic body radiation therapy dose escalation for borderline resectable pancreatic cancer after modified FOLFIRINOX (NCT01446458). Int J Radiat Oncol Biol Phys. 2016;96(2):296–303.CrossRefPubMedGoogle Scholar
  9. 9.
    Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010;37(8):4078–101.CrossRefPubMedGoogle Scholar
  10. 10.
    Goldsmith C, Price P, Cross T, Loughlin S, Cowley I, Plowman N. Dose-volume histogram analysis of stereotactic body radiotherapy treatment of pancreatic cancer: a focus on duodenal dose constraints. Semin Radiat Oncol. 2016;26(2):149–56.CrossRefPubMedGoogle Scholar
  11. 11.
    Rwigema JC, Parikh SD, Heron DE, et al. Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas. Am J Clin Oncol. 2011;34(1):63–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Didolkar MS, Coleman CW, Brenner MJ, et al. Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma results of first 85 patients. J Gastrointest Surg. 2010;14(10):1547–59.CrossRefPubMedGoogle Scholar
  13. 13.
    Chang DT, Schellenberg D, Shen J, et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer. 2009;115(3):665–72.CrossRefPubMedGoogle Scholar
  14. 14.
    Dagoglu N, Callery M, Moser J, et al. Stereotactic body radiotherapy (SBRT) reirradiation for recurrent pancreas cancer. J Cancer. 2016;7(3):283–8.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Lominska CE, Unger K, Nasr NM, Haddad N, Gagnon G. Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas. Radiat Oncol. 2012;7:74.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Kyle Wang
    • 1
  • Andrew Z. Wang
    • 1
  • Joel E. Tepper
    • 1
  1. 1.Department of Radiation OncologyUniversity of North Carolina HospitalsChapel HillUSA

Personalised recommendations